Finanzen von Curanex Pharmaceuticals Inc (CURX)CURXCuranex Pharmaceuticals Inc

Evaluating the bottom line, Curanex Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -411.10%, provide a clear picture of how effectively CURX converts its operational activities into shareholder value.

In the context of the broader market, CURX competes directly with industry leaders such as BNKK and NAII. With a market capitalization of $9.62M, it holds a leading position in the sector. When comparing efficiency, CURX's gross margin of N/A stands against BNKK's 33.61% and NAII's 5.00%. Such benchmarking helps identify whether Curanex Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Curanex has reported substantial net losses, with Q2 2026 net income at -3,290,970 USD and a negative EPS of -2.32. Despite these losses, the company has a current ratio of 45.95, indicating good short-term liquidity.